These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36853332)

  • 1. Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor.
    Deventer MH; Persson M; Laus A; Pottie E; Cannaert A; Tocco G; Gréen H; Stove CP
    Arch Toxicol; 2023 May; 97(5):1367-1384. PubMed ID: 36853332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
    Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
    Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBOMes-Highly Potent and Toxic Alternatives of LSD.
    Zawilska JB; Kacela M; Adamowicz P
    Front Neurosci; 2020; 14():78. PubMed ID: 32174803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
    Kamińska K; Świt P; Malek K
    J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.
    Halberstadt AL
    Curr Top Behav Neurosci; 2017; 32():283-311. PubMed ID: 28097528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats.
    Herian M; Wojtas A; Kamińska K; Świt P; Wach A; Gołembiowska K
    Neurotox Res; 2019 Jul; 36(1):91-100. PubMed ID: 30989482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.
    Vandeputte MM; Cannaert A; Stove CP
    Arch Toxicol; 2020 Nov; 94(11):3819-3830. PubMed ID: 32734307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT
    Pottie E; Dedecker P; Stove CP
    Biochem Pharmacol; 2020 Dec; 182():114251. PubMed ID: 32998000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays.
    Vandeputte MM; Persson M; Walther D; Vikingsson S; Kronstrand R; Baumann MH; Gréen H; Stove CP
    Arch Toxicol; 2022 Mar; 96(3):877-897. PubMed ID: 35072756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanosensor for Sensitive Detection of the New Psychedelic Drug 25I-NBOMe.
    Garrido E; Alfonso M; Díaz de Greñu B; Lozano-Torres B; Parra M; Gaviña P; Marcos MD; Martínez-Máñez R; Sancenón F
    Chemistry; 2020 Mar; 26(13):2813-2816. PubMed ID: 31943443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the Putative Binding Site of a Benzimidazole Opioid (Etazene) and Its Metabolites at µ-Opioid Receptor: A Human Liver Microsomal Assay and Systematic Computational Study.
    Chaturvedi K; Hewamanna I; Pandey P; Khan W; Wang YH; Chittiboyina AG; Doerksen RJ; Godfrey M
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
    Schetz D; Schetz A; Kocić I
    Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
    Halberstadt AL; Geyer MA
    Neuropharmacology; 2014 Feb; 77():200-7. PubMed ID: 24012658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe.
    Laskowski LK; Elbakoush F; Calvo J; Exantus-Bernard G; Fong J; Poklis JL; Poklis A; Nelson LS
    J Med Toxicol; 2015 Jun; 11(2):237-41. PubMed ID: 25387562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Demonstration of 25I-NBOMe Acute Poisoning Using Hair Analysis.
    Ameline A; Farrugia A; Raul JS; Kintz P
    Curr Pharm Biotechnol; 2017; 18(10):786-790. PubMed ID: 29189143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DARK Classics in Chemical Neuroscience: NBOMes.
    Poulie CBM; Jensen AA; Halberstadt AL; Kristensen JL
    ACS Chem Neurosci; 2020 Dec; 11(23):3860-3869. PubMed ID: 31657895
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor.
    Pottie E; Cannaert A; Stove CP
    Arch Toxicol; 2020 Oct; 94(10):3449-3460. PubMed ID: 32627074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin 2A Receptor (5-HT
    Pottie E; Kupriyanova OV; Brandt AL; Laprairie RB; Shevyrin VA; Stove CP
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):479-487. PubMed ID: 33860178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
    Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
    Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe.
    Tang MH; Ching CK; Tsui MS; Chu FK; Mak TW
    Clin Toxicol (Phila); 2014 Jun; 52(5):561-5. PubMed ID: 24779864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.